Results 211 to 220 of about 5,930 (239)

Sites of analgesic action of dynorphin

Life Sciences, 1983
Analgesic effects of dynorphin and dynorphin-(1-13) injected into various regions of the CNS of rats were investigated using the tail pinch method. Dynorphin and dynorphin-(1-13) produced a dose-dependent analgesic effect when injected into the third ventricle (3rd vent.) or the nuclei reticularis gigantocellularis and paragigantocellularis (NRGC-NRPG)
T, Kaneko, T, Nakazawa, M, Ikeda, K, Yamatsu, T, Iwama, T, Wada, M, Satoh, H, Takagi   +7 more
openaire   +2 more sources

Cytokine involvement in dynorphin-induced allodynia

Pain, 2000
Dynorphin A is an endogenous opioid peptide, which has previously been shown to produce a long-lasting allodynia and hyperalgesia in mice, behavioral states consistent with signs of clinically observed neuropathic pain. This dynorphin-induced allodynia was used as a pharmacological, central model of neuropathic pain.
T M, Laughlin, J R, Bethea, R P, Yezierski, G L, Wilcox   +3 more
openaire   +2 more sources

Dynorphin Peptides: Antagonists of Melanocortin Receptors

Pharmaceutical Research, 1997
To identify possible targets that mediate the non-opioid effects of dynorphin-A (DynA), effects that include inflammation and aggravation of traumatic nerve injury.We examined dynorphin peptides for functional interaction with the closely related melanocortin (MC) system.DynA-(1-13)NH2 and other related opioid dynorphin peptides antagonize the human ...
J M, Quillan, W, Sadée
openaire   +2 more sources

Dysregulation of dynorphins in Alzheimer disease

Neurobiology of Aging, 2007
The opioid peptides dynorphins may be involved in pathogenesis of Alzheimer disease (AD) by inducing neurodegeneration or cognitive impairment. To test this hypothesis, the dynorphin system was analyzed in postmortem samples from AD and control subjects, and subjects with Parkinson or cerebro-vascular diseases for comparison.
T, Yakovleva, Z, Marinova, A, Kuzmin, N G, Seidah, V, Haroutunian, L, Terenius, G, Bakalkin   +6 more
openaire   +2 more sources

Two “big” dynorphins from porcine pituitary

Life Sciences, 1982
Abstract Two dynorphins of 24 and 32 residues, respectively, were isolated from porcine pituitary and sequenced. They both contain the dynorphin heptadecapeptide, now designated dynorphin A, at the amino terminus, followed immediately by the putative processing signal Lys-Arg.
W, Fischli, A, Goldstein, M W, Hunkapiller, L E, Hood   +3 more
openaire   +2 more sources

Dynorphin Agonist Therapy of Parkinsonʼs Disease

Clinical Neuropharmacology, 1993
Striatal dynorphin system function may be altered in Parkinson's disease. To evaluate whether treatment with a selective dynorphin agonist improves motor symptoms, four parkinsonian patients received single daily injections of spiradoline under controlled conditions. Doses ranging from 1 to 4 micrograms/kg had no discernible effect on motor performance
M, Giuffra, M M, Mouradian, T L, Davis, J, Ownby, T N, Chase   +4 more
openaire   +2 more sources

Dynorphin receptor in the blood vessel

Neuropeptides, 1985
Using (3H)etorphine, (3H)E, in binding studies, the KD and Bmax for rabbit mesentery and aorta membrane preparations were 0.61 nM and 0.17 fmol/mg tissue respectively, while it was 0.30 nM and 12 fmol/mg tissue in the brain. The IC50 of dynorphin (1-13) (D1-13) for displacing (3H)E binding in the blood vessel was 20 +/- 2.8 nM (S,E,M,), while PLO17, D ...
F Y, Sun, A Z, Zhang
openaire   +2 more sources

Dynorphin peptides in human substantia nigra

Neuropeptides, 1985
Stepwise processing of the prohormone for dynorphin-related peptides, proenkephalin B, may generate a large number of opioid peptides. It is therefore important to perform a chemical characterization of the immunoreactive dynorphin (ir-dyn) found in different tissues. In this study dynorphin peptides in human substantia nigra were characterized. Highly
I, Christensson-Nylander, L, Terenius
openaire   +2 more sources

Epilepsy, CNS viral injury and dynorphin

Trends in Pharmacological Sciences, 2004
Epilepsy is a significant health problem. Despite the widespread use of both classic and newer pharmacological agents that target ion channels, amino acid transmission or receptors, there are numerous examples of mono- or polytherapy being ineffective.
Marylou V, Solbrig, George F, Koob
openaire   +2 more sources

Dynorphins other than dynorphin A(1-17) lack spinal antianalgesic activity but do act on dynorphin A(1-17) receptors.

The Journal of Pharmacology and Experimental Therapeutics, 1991
In recent publications we have proposed that dynorphin (Dyn) A(1-17) functions as an antianalgesic modulator to oppose opioid-induced antinociception in mice. In the present experiments using the tail-flick response in mice, other Dyns [Dyn A(1-8), Dyn A(1-13), Dyn A(2-17), Dyn B and alpha- and beta-neoendorphin] when administered intrathecally (i.t ...
J J, Rady, J M, Fujimoto, L F, Tseng
openaire   +2 more sources